Olumiant Tablet, Film Coated
Product Images NDC 0002-4182

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Olumiant (NDC 0002-4182). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Olumiant Uspi Chem V1)

Chemical structure diagram of baricitinib, the active ingredient in Olumiant. The diagram depicts the molecular arrangement of bars and rings characteristic of the compound.*

FDA Label Image

Figure 1 (Olumiant Uspi F1 V3)

A pharmacokinetic (PK) ratio chart showing AUC and Cmax ratios with 90% confidence intervals for various intrinsic factors relative to a reference for baricitinib (Olumiant). The chart includes factors such as weight, age, sex, race, renal and hepatic impairment, with dosage adjustment recommendations indicated for mild, moderate, and severe renal impairment.*

FDA Label Image

Figure 2 (Olumiant Uspi F2 V1)

A chart depicting pharmacokinetic (PK) ratios and 90% confidence intervals (CI) for coadministered drugs with baricitinib, including Methotrexate, Simvastatin, Ethinyl Estradiol, Levonorgestrel, and Digoxin. The x-axis shows the ratio relative to reference (0.0 to 2.0), with all ratios near 1.0, and recommendations indicating no dosage adjustments are needed for these drug interactions.*

FDA Label Image

Figure 3 (Olumiant Uspi F3 V3)

A forest plot chart displaying the pharmacokinetic interaction ratios and 90% confidence intervals for Olumiant (baricitinib) coadministered with various drugs. The chart shows ratios for AUC and Cmax relative to reference, with recommendations such as no dose adjustment for most drugs and half recommended dose with probenecid. Drugs evaluated include ketoconazole, fluconazole, rifampicin, probenecid, simulated ibuprofen and diclofenac, methotrexate, cyclosporine, and omeprazole.*

FDA Label Image

Figure 4 (Olumiant Uspi F4 V2)

A line graph comparing the percent responders over 24 weeks between Olumiant 2 mg (baricitinib) and placebo groups. The y-axis shows percent responders from 0 to 100%, and the x-axis shows weeks from 0 to 24. Olumiant 2 mg shows a higher and increasing percentage of responders compared to placebo throughout the study period.*

FDA Label Image

Figure (Olumiant Uspi F5 V1)

Two line graphs labeled Trial AA-1 and Trial AA-2 depict percent responders over 36 weeks comparing placebo, Olumiant 2 mg, and Olumiant 4 mg. The y-axis represents percent responders and the x-axis represents weeks. Both trials show an increase in responders for Olumiant 2 mg and 4 mg over time, with the 4 mg dose showing the highest responder percentage, while placebo remains low and nearly flat throughout.*

FDA Label Image

Figure (Olumiant Uspi F6 V1)

A line graph titled 'AA-PEDS' showing the proportion of patients with SALT scores of 20 or less over 36 weeks. It compares placebo, baricitinib 2 mg, and baricitinib 4 mg treatments, with baricitinib 4 mg showing the highest increase, followed by 2 mg, and placebo remaining lowest throughout.*

FDA Label Image

Package Label – Olumiant 2 mg 30ct Bottle (Olumiant 2mg 30ct 034 05)

Olumiant (baricitinib) tablets 2 mg film-coated oral tablets label. The package contains 30 tablets and is labeled for prescription use only. The label includes the manufacturer name Lilly and instructions to dispense with the medication guide. The NDC on the label is 0002-4182-30.*

FDA Label Image

Package Label – Olumiant 1 mg 30ct Bottle (Olumiant 1mg 30ct 066 05)

Olumiant (baricitinib) tablets 1 mg film-coated oral tablets in a 30-count package. The label features the Eli Lilly and Company branding and includes instructions to dispense with a medication guide. It also displays storage conditions, a barcode, and a National Drug Code (NDC) 0002-4732-30.*

FDA Label Image

Package Label – Olumiant 4 mg 30ct Bottle (Olumiant 4mg 30ct 073 03)

Label for Olumiant 4 mg (baricitinib) tablets, film-coated oral tablets. The label shows the strength as 4 mg and the package count as 30 tablets. Labeler is Eli Lilly and Company. The label includes instructions to dispense with a medication guide and storage conditions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.